Infliximab for the Treatment of Extensive Plaque Psoriasis ± Regulation, Cost and Reimbursement

Mordi Rabinovich BPharm MBA1 and Menahem Fainaru MD1,2 1 Maccabi Healthcare Services, Tel Aviv, Israel 2

Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel

The case reported by Amital et al. in this issue of IMAJ [1], in
addition to its impressive results, raises one of the most difficult
dilemmas of modern medicine ± the economic possibilities of
modern society lagging behind the technological potential, an issue
aggravated by the Regulator and Courts.